Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog.

Hövelmann U, Bysted BV, Mouritzen U, Macchi F, Lamers D, Kronshage B, Møller DV, Heise T

Diabetes care22 Dec 2017Cited by 84 (Europe PMC)

PMID29273578DOI10.2337/dc17-1402PepBankPUB-29273578

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study16

16 results from studies that gave the peptide. 16 results from people.

01HumanRandomized controlled trialPharmacokinetics
In type 1 diabetes, dasiglucagon plasma concentrations increased rapidly and dose-dependently.
In plain wordsDasiglucagon blood levels increased rapidly with increasing doses.
Peptide
Dasiglucagon
Outcome
IncreasePlasma exposure
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
0.1-1.0 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
Dasiglucagon demonstrated a dose-dependent and rapid increase in plasma concentrations, reaching a maximum at ∼35 min with a half-life of ∼0.5 h.
1 context sentence(design, population, supporting numbers)
Summary · context
In this single-center, randomized, double-blind trial, 58 patients with type 1 diabetes received single subcutaneous injections of 0.1, 0.3, 0.6, or 1.0 mg dasiglucagon or 0.5 or 1.0 mg GlucaGen in a state of hypoglycemia (blood glucose target 55 mg/dL) induced by an intravenous insulin infusion.
Report a problemFND-2927357801
02HumanRandomized controlled trialEfficacy outcome
Dasiglucagon increased glucose by ≥20 mg/dL in 9-14 min, similar to GlucaGen in type 1 diabetes.
In plain wordsDasiglucagon raised glucose within 9-14 minutes, similar to GlucaGen.
Peptide
Dasiglucagon
Outcome
Not applicableTime to glucose increase
Study
n: not reported in source
Comparator
GlucaGen
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.1, 0.3, 0.6, or 1.0 mg · subcutaneousAs given in this study (human).
Measurements
Time to PG increase of ≥20 mg/dL
9 to 14 min
dasiglucagon, range across doses
Source sentences
Summary
Dasiglucagon rapidly increased plasma glucose (PG) by ≥20 mg/dL (9-14 min) to PG ≥70 mg/dL (within 6-10 min), similar to GlucaGen, but with a longer-lasting and greater effect on PG.
1 context sentence(design, population, supporting numbers)
Summary · context
In this single-center, randomized, double-blind trial, 58 patients with type 1 diabetes received single subcutaneous injections of 0.1, 0.3, 0.6, or 1.0 mg dasiglucagon or 0.5 or 1.0 mg GlucaGen in a state of hypoglycemia (blood glucose target 55 mg/dL) induced by an intravenous insulin infusion.
Report a problemFND-2927357804
03HumanRandomized controlled trialEfficacy outcome
Dasiglucagon raised glucose to ≥70 mg/dL within 6-10 min, similar to GlucaGen.
In plain wordsDasiglucagon restored glucose to the reported threshold within 6-10 minutes, similar to GlucaGen.
Peptide
Dasiglucagon
Outcome
Not applicableTime to glucose threshold
Study
n: not reported in source
Comparator
GlucaGen
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.1, 0.3, 0.6, or 1.0 mg · subcutaneousAs given in this study (human).
Measurements
Time to PG ≥70 mg/dL
6 to 10 min
dasiglucagon, range across doses
Source sentences
Summary
Dasiglucagon rapidly increased plasma glucose (PG) by ≥20 mg/dL (9-14 min) to PG ≥70 mg/dL (within 6-10 min), similar to GlucaGen, but with a longer-lasting and greater effect on PG.
1 context sentence(design, population, supporting numbers)
Summary · context
In this single-center, randomized, double-blind trial, 58 patients with type 1 diabetes received single subcutaneous injections of 0.1, 0.3, 0.6, or 1.0 mg dasiglucagon or 0.5 or 1.0 mg GlucaGen in a state of hypoglycemia (blood glucose target 55 mg/dL) induced by an intravenous insulin infusion.
Report a problemFND-2927357805
04HumanRandomized controlled trialEfficacy outcome
Dasiglucagon had a longer-lasting glucose effect than GlucaGen in type 1 diabetes.
In plain wordsDasiglucagon's glucose effect lasted longer than GlucaGen's effect.
Peptide
Dasiglucagon
Outcome
IncreaseGlucose response duration
Study
n: not reported in source
Comparator
GlucaGen
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.1, 0.3, 0.6, or 1.0 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
Dasiglucagon rapidly increased plasma glucose (PG) by ≥20 mg/dL (9-14 min) to PG ≥70 mg/dL (within 6-10 min), similar to GlucaGen, but with a longer-lasting and greater effect on PG.
1 context sentence(design, population, supporting numbers)
Summary · context
In this single-center, randomized, double-blind trial, 58 patients with type 1 diabetes received single subcutaneous injections of 0.1, 0.3, 0.6, or 1.0 mg dasiglucagon or 0.5 or 1.0 mg GlucaGen in a state of hypoglycemia (blood glucose target 55 mg/dL) induced by an intravenous insulin infusion.
Report a problemFND-2927357806
05HumanRandomized controlled trialEfficacy outcome
Dasiglucagon had a greater glucose effect than GlucaGen in type 1 diabetes.
In plain wordsDasiglucagon raised glucose more than GlucaGen.
Peptide
Dasiglucagon
Outcome
IncreaseGlucose response magnitude
Study
n: not reported in source
Comparator
GlucaGen
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.1, 0.3, 0.6, or 1.0 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
Dasiglucagon rapidly increased plasma glucose (PG) by ≥20 mg/dL (9-14 min) to PG ≥70 mg/dL (within 6-10 min), similar to GlucaGen, but with a longer-lasting and greater effect on PG.
1 context sentence(design, population, supporting numbers)
Summary · context
In this single-center, randomized, double-blind trial, 58 patients with type 1 diabetes received single subcutaneous injections of 0.1, 0.3, 0.6, or 1.0 mg dasiglucagon or 0.5 or 1.0 mg GlucaGen in a state of hypoglycemia (blood glucose target 55 mg/dL) induced by an intravenous insulin infusion.
Report a problemFND-2927357807
06HumanRandomized controlled trialEfficacy outcome
In type 1 diabetes, GlucaGen had a similar early glucose response to dasiglucagon.
In plain wordsGlucaGen and dasiglucagon produced similar early glucose responses.
Peptide
Glucagon
Outcome
Not applicableEarly glucose response
Study
n: not reported in source
Comparator
Dasiglucagon
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.5 or 1.0 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
Dasiglucagon rapidly increased plasma glucose (PG) by ≥20 mg/dL (9-14 min) to PG ≥70 mg/dL (within 6-10 min), similar to GlucaGen, but with a longer-lasting and greater effect on PG.
1 context sentence(design, population, supporting numbers)
Summary · context
In this single-center, randomized, double-blind trial, 58 patients with type 1 diabetes received single subcutaneous injections of 0.1, 0.3, 0.6, or 1.0 mg dasiglucagon or 0.5 or 1.0 mg GlucaGen in a state of hypoglycemia (blood glucose target 55 mg/dL) induced by an intravenous insulin infusion.
Report a problemFND-2927357810
07HumanRandomized controlled trialEfficacy outcome
In type 1 diabetes, GlucaGen had a shorter-lasting glucose effect than dasiglucagon.
In plain wordsGlucaGen's glucose effect lasted less time than dasiglucagon's effect.
Peptide
Glucagon
Outcome
DecreaseGlucose response duration
Study
n: not reported in source
Comparator
Dasiglucagon
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.5 or 1.0 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
Dasiglucagon rapidly increased plasma glucose (PG) by ≥20 mg/dL (9-14 min) to PG ≥70 mg/dL (within 6-10 min), similar to GlucaGen, but with a longer-lasting and greater effect on PG.
1 context sentence(design, population, supporting numbers)
Summary · context
In this single-center, randomized, double-blind trial, 58 patients with type 1 diabetes received single subcutaneous injections of 0.1, 0.3, 0.6, or 1.0 mg dasiglucagon or 0.5 or 1.0 mg GlucaGen in a state of hypoglycemia (blood glucose target 55 mg/dL) induced by an intravenous insulin infusion.
Report a problemFND-2927357811
08HumanRandomized controlled trialEfficacy outcome
In type 1 diabetes, GlucaGen had a smaller glucose effect than dasiglucagon.
In plain wordsGlucaGen raised glucose less than dasiglucagon.
Peptide
Glucagon
Outcome
DecreaseGlucose response magnitude
Study
n: not reported in source
Comparator
Dasiglucagon
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.5 or 1.0 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
Dasiglucagon rapidly increased plasma glucose (PG) by ≥20 mg/dL (9-14 min) to PG ≥70 mg/dL (within 6-10 min), similar to GlucaGen, but with a longer-lasting and greater effect on PG.
1 context sentence(design, population, supporting numbers)
Summary · context
In this single-center, randomized, double-blind trial, 58 patients with type 1 diabetes received single subcutaneous injections of 0.1, 0.3, 0.6, or 1.0 mg dasiglucagon or 0.5 or 1.0 mg GlucaGen in a state of hypoglycemia (blood glucose target 55 mg/dL) induced by an intravenous insulin infusion.
Report a problemFND-2927357812
09HumanRandomized controlled trialSafety outcome
Nausea was the most frequent adverse event and occurred at a similar rate with dasiglucagon and GlucaGen (44-56%).
In plain wordsNausea rates were similar with dasiglucagon and GlucaGen.
Peptide
Dasiglucagon
Outcome
Not applicableNausea
Study
n: not reported in source
Comparator
GlucaGen
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0.1, 0.3, 0.6, or 1.0 mg · subcutaneousAs given in this study (human).
Measurements
Nausea incidence
44 to 56%
Across dasiglucagon and GlucaGen groups ('similar rate')
Source sentences
Summary
Nausea was the most frequent adverse event, occurring at a similar rate (44-56%).
1 context sentence(design, population, supporting numbers)
Summary · context
In this single-center, randomized, double-blind trial, 58 patients with type 1 diabetes received single subcutaneous injections of 0.1, 0.3, 0.6, or 1.0 mg dasiglucagon or 0.5 or 1.0 mg GlucaGen in a state of hypoglycemia (blood glucose target 55 mg/dL) induced by an intravenous insulin infusion.
Report a problemFND-2927357815
10HumanRandomized controlled trialSafety outcome
Nausea was the most frequent adverse event and occurred at a similar rate with GlucaGen and dasiglucagon (44-56%).
In plain wordsNausea rates were similar with GlucaGen and dasiglucagon.
Peptide
Glucagon
Outcome
Not applicableNausea
Study
n: not reported in source
Comparator
Dasiglucagon
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0.5 or 1.0 mg · subcutaneousAs given in this study (human).
Measurements
Nausea incidence
44 to 56%
Across dasiglucagon and GlucaGen groups ('similar rate')
Source sentences
Summary
Nausea was the most frequent adverse event, occurring at a similar rate (44-56%).
1 context sentence(design, population, supporting numbers)
Summary · context
In this single-center, randomized, double-blind trial, 58 patients with type 1 diabetes received single subcutaneous injections of 0.1, 0.3, 0.6, or 1.0 mg dasiglucagon or 0.5 or 1.0 mg GlucaGen in a state of hypoglycemia (blood glucose target 55 mg/dL) induced by an intravenous insulin infusion.
Report a problemFND-2927357816
11HumanNon-randomized trialPharmacokinetics
Dasiglucagon reached maximum plasma concentration at ∼35 min in type 1 diabetes.
In plain wordsDasiglucagon blood levels peaked at about 35 minutes.
Peptide
Dasiglucagon
Outcome
Not applicableTime to maximum concentration
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
0.1, 0.3, 0.6, or 1.0 mg · subcutaneousAs given in this study (human).
Measurements
Time to maximum plasma concentration
≈ 35 min
dasiglucagon
Source sentences
Summary
Dasiglucagon demonstrated a dose-dependent and rapid increase in plasma concentrations, reaching a maximum at ∼35 min with a half-life of ∼0.5 h.
1 context sentence(design, population, supporting numbers)
Summary · context
In this single-center, randomized, double-blind trial, 58 patients with type 1 diabetes received single subcutaneous injections of 0.1, 0.3, 0.6, or 1.0 mg dasiglucagon or 0.5 or 1.0 mg GlucaGen in a state of hypoglycemia (blood glucose target 55 mg/dL) induced by an intravenous insulin infusion.
Report a problemFND-2927357802
12HumanNon-randomized trialPharmacokinetics
Dasiglucagon half-life was ∼0.5 h in type 1 diabetes.
In plain wordsDasiglucagon had a half-life of about half an hour.
Peptide
Dasiglucagon
Outcome
Not applicableHalf-life
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
0.1, 0.3, 0.6, or 1.0 mg · subcutaneousAs given in this study (human).
Measurements
Half-life
≈ 0.5 h
dasiglucagon
Source sentences
Summary
Dasiglucagon demonstrated a dose-dependent and rapid increase in plasma concentrations, reaching a maximum at ∼35 min with a half-life of ∼0.5 h.
1 context sentence(design, population, supporting numbers)
Summary · context
In this single-center, randomized, double-blind trial, 58 patients with type 1 diabetes received single subcutaneous injections of 0.1, 0.3, 0.6, or 1.0 mg dasiglucagon or 0.5 or 1.0 mg GlucaGen in a state of hypoglycemia (blood glucose target 55 mg/dL) induced by an intravenous insulin infusion.
Report a problemFND-2927357803
13HumanNon-randomized trialEfficacy outcome
All dasiglucagon recipients reached both glucose endpoints within 30 min.
In plain wordsAll dasiglucagon recipients reached both glucose targets within 30 minutes.
Peptide
Dasiglucagon
Outcome
Not applicableRecovery success within 30 minutes
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.1, 0.3, 0.6, or 1.0 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
All patients on both treatments reached these end points within 30 min (predefined success criteria).
2 context sentences(design, population, supporting numbers)
Summary · context
Dasiglucagon rapidly increased plasma glucose (PG) by ≥20 mg/dL (9-14 min) to PG ≥70 mg/dL (within 6-10 min), similar to GlucaGen, but with a longer-lasting and greater effect on PG.
Summary · context
In this single-center, randomized, double-blind trial, 58 patients with type 1 diabetes received single subcutaneous injections of 0.1, 0.3, 0.6, or 1.0 mg dasiglucagon or 0.5 or 1.0 mg GlucaGen in a state of hypoglycemia (blood glucose target 55 mg/dL) induced by an intravenous insulin infusion.
Report a problemFND-2927357808
14HumanNon-randomized trialEfficacy outcome
All GlucaGen recipients reached both glucose endpoints within 30 min.
In plain wordsAll GlucaGen recipients reached both glucose targets within 30 minutes.
Peptide
Glucagon
Outcome
Not applicableRecovery success within 30 minutes
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.5 or 1.0 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
All patients on both treatments reached these end points within 30 min (predefined success criteria).
2 context sentences(design, population, supporting numbers)
Summary · context
Dasiglucagon rapidly increased plasma glucose (PG) by ≥20 mg/dL (9-14 min) to PG ≥70 mg/dL (within 6-10 min), similar to GlucaGen, but with a longer-lasting and greater effect on PG.
Summary · context
In this single-center, randomized, double-blind trial, 58 patients with type 1 diabetes received single subcutaneous injections of 0.1, 0.3, 0.6, or 1.0 mg dasiglucagon or 0.5 or 1.0 mg GlucaGen in a state of hypoglycemia (blood glucose target 55 mg/dL) induced by an intravenous insulin infusion.
Report a problemFND-2927357809
15HumanNon-randomized trialSafety outcome
Dasiglucagon was well tolerated in patients with type 1 diabetes.
In plain wordsPatients tolerated dasiglucagon well.
Peptide
Dasiglucagon
Outcome
Not applicableTolerability
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
0.1, 0.3, 0.6, or 1.0 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
Both treatments were well tolerated.
1 context sentence(design, population, supporting numbers)
Summary · context
In this single-center, randomized, double-blind trial, 58 patients with type 1 diabetes received single subcutaneous injections of 0.1, 0.3, 0.6, or 1.0 mg dasiglucagon or 0.5 or 1.0 mg GlucaGen in a state of hypoglycemia (blood glucose target 55 mg/dL) induced by an intravenous insulin infusion.
Report a problemFND-2927357813
16HumanNon-randomized trialSafety outcome
GlucaGen was well tolerated in patients with type 1 diabetes.
In plain wordsPatients tolerated GlucaGen well.
Peptide
Glucagon
Outcome
Not applicableTolerability
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
0.5 or 1.0 mg · subcutaneousAs given in this study (human).
Source sentences
Summary
Both treatments were well tolerated.
1 context sentence(design, population, supporting numbers)
Summary · context
In this single-center, randomized, double-blind trial, 58 patients with type 1 diabetes received single subcutaneous injections of 0.1, 0.3, 0.6, or 1.0 mg dasiglucagon or 0.5 or 1.0 mg GlucaGen in a state of hypoglycemia (blood glucose target 55 mg/dL) induced by an intravenous insulin infusion.
Report a problemFND-2927357814

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT02660008

Single Doses of ZP4207 Adm. sc to Hypoglycemic TD1 pt. to Describe the PK and PD of ZP4207 as Comp. to Marketed Glucagon

Zealand Pharman = 81Jan 2016 to Jun 2016

Hypoglycemia

Trial page ClinicalTrials.govUpdated 15 Jun 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 2
27 Oct 2026, 16:35 UTC
Study data updated · source update from Europe PMC
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC